{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:38:44Z","timestamp":1789191524394,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.seizure.2022.09.020","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T01:40:38Z","timestamp":1664415638000},"page":"54-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Efficacy and safety of perampanel in epilepsy: A systematic review and meta-analysis of randomised controlled trials"],"prefix":"10.1016","volume":"102","author":[{"given":"Alekhya","family":"Lavu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Aboulatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Abou-Setta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basma","family":"Aloud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Askin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasheda","family":"Rabbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Shouman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Zarychanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif","family":"Eltonsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2022.09.020_bib0001","unstructured":"WHO. Epilepsy: A Public Health Imperative.; 2019. https:\/\/www.who.int\/mental_health\/neurology\/epilepsy\/report_2019\/en\/."},{"key":"10.1016\/j.seizure.2022.09.020_bib0002","unstructured":"National Institute of Neurological Disorders and Stroke. The Epilepsies and Seizures. 2018."},{"issue":"4","key":"10.1016\/j.seizure.2022.09.020_bib0003","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1192\/bjpo.bp.115.002345","article-title":"Psychosocial aspects of epilepsy: a wider approach","volume":"2","author":"Mula","year":"2016","journal-title":"BJPsych Open"},{"key":"10.1016\/j.seizure.2022.09.020_bib0004","unstructured":"Nguyen V V, Baca CB, Chen JJ, Rogers SJ. Chapter 56\u00a0: Epilepsy. 2021."},{"issue":"7","key":"10.1016\/j.seizure.2022.09.020_bib0005","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1528-1167.2011.03109.x","article-title":"Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy","volume":"52","author":"Hanada","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2022.09.020_bib0006","article-title":"Full Prescribing Information Perampanel","year":"2012","journal-title":"Clin Trials"},{"issue":"February","key":"10.1016\/j.seizure.2022.09.020_bib0007","article-title":"Efficacy, tolerability and safety of perampanel in population with pharmacoresistant focal seizures: A systematic review and meta-analysis","volume":"182","author":"Mahajan","year":"2022","journal-title":"Epilepsy Res"},{"issue":"10","key":"10.1016\/j.seizure.2022.09.020_bib0008","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40263-013-0091-9","article-title":"Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy","volume":"27","author":"Hsu","year":"2013","journal-title":"CNS Drugs"},{"issue":"11","key":"10.1016\/j.seizure.2022.09.020_bib0009","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.seizure.2022.09.020_bib0010","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/ane.12883","article-title":"Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study","volume":"137","author":"Nishida","year":"2018","journal-title":"Acta Neurol Scand"},{"issue":"7","key":"10.1016\/j.seizure.2022.09.020_bib0011","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/epi.13417","article-title":"Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety","volume":"57","author":"Lagae","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2022.09.020_bib0012","first-page":"2020","article-title":"PRISMA 2020 Checklist","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.seizure.2022.09.020_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.seizure.2022.09.020_bib0014","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.seizure.2022.09.020_bib0015","unstructured":"RevMan User guide. Welcome to RevMan 5 . 4. 2020;4(May). https:\/\/training.cochrane.org\/system\/files\/uploads\/protected_file\/RevMan5.4_user_guide.pdf."},{"key":"10.1016\/j.seizure.2022.09.020_bib0016","author":"Higgins","year":"2021","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.2"},{"issue":"1","key":"10.1016\/j.seizure.2022.09.020_bib0017","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-0404.2011.01588.x","article-title":"Tolerability and safety of perampanel: Two randomized dose-escalation studies","volume":"125","author":"Krauss","year":"2012","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"10.1016\/j.seizure.2022.09.020_bib0018","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"issue":"18","key":"10.1016\/j.seizure.2022.09.020_bib0019","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.seizure.2022.09.020_bib0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2022.09.020_bib0021","article-title":"Perampanel FDA 2018","year":"2018","journal-title":"Fda"},{"issue":"2","key":"10.1016\/j.seizure.2022.09.020_bib0022","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/epi.13279","article-title":"Cognitive effects of adjunctive perampanel for partial-onset seizures: A randomized trial","volume":"57","author":"Meador","year":"2016","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2022.09.020_bib0023","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/epi.12504","article-title":"Adverse effects and safety profile of perampanel: a review of pooled data","volume":"55","author":"Rugg-Gunn","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2022.09.020_bib0024","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eplepsyres.2016.08.001","article-title":"Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study","volume":"126","author":"Villanueva","year":"2016","journal-title":"Epilepsy Res"},{"issue":"6","key":"10.1016\/j.seizure.2022.09.020_bib0025","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/1756285616661115","article-title":"Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data","volume":"9","author":"Rohracher","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"issue":"March","key":"10.1016\/j.seizure.2022.09.020_bib0026","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jns.2018.04.017","article-title":"Perampanel as adjunctive therapy in highly refractory epilepsies: Real-world data from an Italian tertiary care epilepsy centre","volume":"390","author":"Morano","year":"2018","journal-title":"J Neurol Sci"},{"issue":"5","key":"10.1016\/j.seizure.2022.09.020_bib0027","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.seizure.2007.12.003","article-title":"Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies","volume":"17","author":"Zaccara","year":"2008","journal-title":"Seizure"},{"issue":"9","key":"10.1016\/j.seizure.2022.09.020_bib0028","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.seizure.2012.07.011","article-title":"The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: A systematic review and indirect comparison","volume":"21","author":"Martyn-St James","year":"2012","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.seizure.2022.09.020_bib0029","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/epi.12492","article-title":"First clinical experiences with perampanel-The Kork experience in 74 patients","volume":"55","author":"Steinhoff","year":"2014","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.seizure.2022.09.020_bib0030","first-page":"11","article-title":"Zombielike\u201d Aggression in Perampanel Overdose","volume":"13","author":"Morsi","year":"2021","journal-title":"Cureus"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131122002187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131122002187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T02:01:59Z","timestamp":1761012119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131122002187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":30,"alternative-id":["S1059131122002187"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2022.09.020","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of perampanel in epilepsy: A systematic review and meta-analysis of randomised controlled trials","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2022.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}